Search
Search Results
##search.searchResults.foundPlural##
-
TUBERCULOSIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
3608PDF: 1360HTML: 8438 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1586PDF: 907HTML: 3155 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3732PDF: 1733HTML: 5990Fig1-Ag-Pil: 292Ag-Pil Fig.2: 289 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
2264PDF: 859HTML: 3289 -
-
PARASITIC INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
3920PDF: 1374HTML: 3976Untitled: 290Untitled: 321 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1479PDF: 588HTML: 312 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2772PDF: 893HTML: 5408 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1653PDF: 1359HTML: 546 -
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT
1676HTML: 433PDF: 1044Suppl. Files: 531 -
ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
4511PDF: 1479HTML: 2214 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
2099PDF: 1142HTML: 277 -
DISTRIBUTION OF DNA DAMAGE REPAIR GENE POLYMORPHISM hOGG1, XRCC1 and p53 AMONG SICKLE CELL DISEASE PATIENTS IN INDIA
1686PDF: 866HTML: 1551Table Genotype and allele frequencies of hOGG1 codon 326 Ser>Cys and p53 72Arg>Pro polymorphisms among SCD patients and control group: 230 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2529PDF: 1414HTML: 17245Bassan Fig.1: 188Bassan Fig.2: 293Bassan Fig.4: 177Fig.3: 315 -
CYTOMEGALOVIRUS REACTIVATION IN ADULT RECIPIENTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
1646PDF: 994HTML: 1035figures: 240table 1: 247table2: 241table3: 249 -
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1327PDF: 660HTML: 6943 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1704PDF: 1115HTML: 153 -
END-OF-LIFE CARE IN SICKLE CELL DISEASE AND TRANSFUSION-DEPENDENT β-THALASSEMIA: CLINICAL, PSYCHOLOGICAL, AND ETHICAL CONSIDERATIONS Challenges in Supportive Care, Equity, and Compassion at End of Life
1321PDF: 916Html: 216 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2763PDF: 960HTML: 17627Fig1 Caligaris: 246Fig.2 Caliga: 282 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1904PDF: 1448HTML: 676 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
6011PDF: 1628HTML: 1689Untitled: 289 -
PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA
2047PDF: 916HTML: 10378Figures 1,2,3: 326 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1943PDF: 584HTML: 375 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3332PDF: 980HTML: 7327Kost Fig1: 236Kost Fig 2: 222Kost Fig3: 243Kost Fig 4: 249Kost Fig5: 246Kost fig 6: 235 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
8008PDF: 2544HTML: 2182Table 1.: 282Table 2.: 303Table 3.: 272Table 4.: 273 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3897PDF: 1002HTML: 6897 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1603PDF: 1431HTML: 126







